Mohammad H. Siddique
Sendai, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α.
Journal: American journal of physiology. Lung cellular and molecular physiology
Published: August 19, 2024
Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
Journal: American journal of physiology. Lung cellular and molecular physiology
Published: January 19, 2022
Identification of Celastrol as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: January 21, 2021
Diagnostic and Prognostic Significance of Serum Levels of SeP (Selenoprotein P) in Patients With Pulmonary Hypertension.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: November 01, 2019
ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure: A Possible Novel Therapeutic Target.
Journal: Circulation research
Published: September 27, 2019
Identification of Emetine as a Therapeutic Agent for Pulmonary Arterial Hypertension: Novel Effects of an Old Drug.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: September 20, 2019
Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension.
Journal: Circulation research
Published: June 15, 2019
Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension.
Journal: International journal of molecular sciences
Published: October 28, 2018
Different roles of myocardial ROCK1 and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in mice.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 11, 2018
Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Journal: Circulation research
Published: January 14, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026